Reimagining Medicine Q2 2023 Results

Supplementary Lead Company overview Innovation: Pipeline overview Financial review Financial performance Conclusions Novartis submission schedule New Molecular Entities: Lead and supplementary indications 2023 iptacopan LNP023 PNH PluvictoⓇ AAA617 mCRPC, Pre-taxane tislelizumab VDT482 1L Gastric Cancer W tislelizumab VDT482 1L ESCC JDQ443 2024 JDQ443 2/3L NSCLC (mono) remibrutinib LOU064 CSU sabatolimab MBG453 HR-MDS Appendix Innovation: Clinical trials References Abbreviations INNOVATION Cardiovascular Immunology Neuroscience Solid tumors Hematology Non-core TA project 2025 pelacarsen TQJ230 CVRR-Lp(a) 177Lu-NeoB AAA603 Multiple Solid Tumors ianalumab VAY736 2L Immune Thrombocytopenia iscalimab CFZ533 Sjögren's syndrome ligelizumab QGE031 Food allergy LNA043 Knee osteoarthritis cipargamin KAE609 Malaria severe ganaplacide/lumefantrine KLU156 Malaria uncomplicated libvatrep² SAF312 COSP ≥2026 MIJ821 Depression Y rapcabtagene autoleucel YTB323 High-risk large B-cell lymphoma TNO155 Solid tumors XXB750 Hypertension LXE408 Visceral leishmaniasis PPY9881 Geographic atrophy iptacopan LNP023 C3G iptacopan LNP023 IgAN PluvictoⓇ AAA617 mHSPC tislelizumab VDT482 1L Small Cell Lung Cancer tislelizumab VDT482 Localized ESCC ianalumab VAY736 1L Immune Thrombocytopenia ianalumab VAY736 WAIHA ianalumab VAY736 АІН ianalumab VAY736 Sjögren's syndrome cipargamin KAE609 Malaria uncomplicated Y до ianalumab VAY736 Lupus Nephritis ianalumab VAY736 SLE iptacopan LNP023 aHUS iptacopan LNP023 IC-MPGN JDQ443 JDQ443 NSCLC (Combo) rapcabtagene autoleucel YTB323 Lupus Nephritis remibrutinib LOU064 Multiple sclerosis remibrutinib LOU064 Sjögren's syndrome sabatolimab MBG453 Unfit AML tislelizumab VDT482 Adj/Neo adj NSCLC tislelizumab VDT482 1L Urothelial cell cancer W 1. Gyroscope acquisition. 2. 'Front of eye' ophthalmology divestment, subject to customary closing conditions; closing expected H2 2023. 36 Investor Relations | Q2 2023 Results NOVARTIS | Reimagining Medicine

View entire presentation